These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 29483045)

  • 1. Active Surveillance for Prostate Cancer: Are We Failing Latino Patients at a Large Safety Net Hospital?
    Ballas LK; Kraus R; Ji L; Groshen S; Stern MC; Gill I; Quinn DI; Chung E; Abreu A; Hamilton AS
    Clin Genitourin Cancer; 2018 Aug; 16(4):e719-e727. PubMed ID: 29483045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of men on active surveillance for low-risk prostate cancer at a safety-net hospital.
    Osterberg EC; Palmer NRA; Harris CR; Murphy GP; Blaschko SD; Chu C; Allen IE; Cooperberg MR; Carroll PR; Breyer BN
    Urol Oncol; 2017 Nov; 35(11):663.e9-663.e14. PubMed ID: 28826701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of Becoming Lost to Follow-up During Active Surveillance for Prostate Cancer.
    Ginsburg KB; Auffenberg GB; Qi J; Powell IJ; Linsell SM; Montie JE; Miller DC; Cher ML
    Eur Urol; 2018 Dec; 74(6):704-707. PubMed ID: 30177290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of clinically localized prostate cancer patients managed with initial monitoring approach versus upfront local treatment: a North American population-based study.
    Abdel-Rahman O
    Clin Transl Oncol; 2019 Dec; 21(12):1673-1679. PubMed ID: 30929179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active Surveillance: A North American Population-Based Study.
    Bandini M; Nazzani S; Marchioni M; Preisser F; Tian Z; Moschini M; Abdollah F; Suardi N; Graefen M; Montorsi F; Shariat SF; Saad F; Briganti A; Karakiewicz PI
    Clin Genitourin Cancer; 2019 Feb; 17(1):72-78.e4. PubMed ID: 30342845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National Comprehensive Cancer Network® Favorable Intermediate Risk Prostate Cancer-Is Active Surveillance Appropriate?
    Aghazadeh MA; Frankel J; Belanger M; McLaughlin T; Tortora J; Staff I; Wagner JR
    J Urol; 2018 May; 199(5):1196-1201. PubMed ID: 29288120
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss to follow-up before and after initiation of antiretroviral therapy in HIV facilities in Lilongwe, Malawi.
    Tweya H; Oboho IK; Gugsa ST; Phiri S; Rambiki E; Banda R; Mwafilaso J; Munthali C; Gupta S; Bateganya M; Maida A
    PLoS One; 2018; 13(1):e0188488. PubMed ID: 29373574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate volume effect on Gleason score upgrading in active surveillance appropriate patients.
    Çamur E; Coşkun A; Kavukoğlu Ӧ; Can U; Kara Ö; Develi Çamur A; Sarıca K; Narter KF
    Arch Ital Urol Androl; 2019 Jul; 91(2):. PubMed ID: 31266273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer.
    Karakiewicz PI; Bhojani N; Neugut A; Shariat SF; Jeldres C; Graefen M; Perrotte P; Peloquin F; Kattan MW
    J Sex Med; 2008 Apr; 5(4):919-927. PubMed ID: 18371045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patterns of care for men diagnosed with prostate cancer in Victoria from 2008 to 2011.
    Evans SM; Millar JL; Davis ID; Murphy DG; Bolton DM; Giles GG; Frydenberg M; Andrianopoulos N; Wood JM; Frauman AG; Costello AJ; McNeil JJ
    Med J Aust; 2013 Jun; 198(10):540-5. PubMed ID: 23725268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lost to follow-up: reasons and characteristics of patients undergoing corneal transplantation at Tenwek Hospital in Kenya, East Africa.
    Ikpoh BI; Kunselman A; Stetter C; Chen M
    Pan Afr Med J; 2020; 36():95. PubMed ID: 32774654
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluating the Safety of Active Surveillance: Outcomes of Deferred Radical Prostatectomy after an Initial Period of Surveillance.
    Balakrishnan AS; Cowan JE; Cooperberg MR; Shinohara K; Nguyen HG; Carroll PR
    J Urol; 2019 Sep; 202(3):506-510. PubMed ID: 30958738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
    Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor Volume on Biopsy of Low Risk Prostate Cancer Managed with Active Surveillance.
    Tosoian JJ; Mamawala M; Patel HD; Alam R; Epstein JI; Ross AE; Carter HB
    J Urol; 2018 Apr; 199(4):954-960. PubMed ID: 29074222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management Strategies and Patient Selection After a Hospital Funding Reform for Prostate Cancer Surgery in Canada.
    Wettstein MS; Palmer KS; Kulkarni GS; Paterson JM; Ling V; Lapointe-Shaw L; Li AH; Brown A; Taljaard M; Ivers N
    JAMA Netw Open; 2019 Aug; 2(8):e1910505. PubMed ID: 31469400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
    Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
    JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Follow-up in Active Surveillance for Prostate Cancer: Strict Protocol Adherence Remains Important for PRIAS-ineligible Patients.
    Soeterik TFW; van Melick HHE; Dijksman LM; Biesma DH; Witjes JA; van Basten JA
    Eur Urol Oncol; 2019 Sep; 2(5):483-489. PubMed ID: 31411970
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate cancer knowledge among low income minority men.
    Deibert CM; Maliski S; Kwan L; Fink A; Connor SE; Litwin MS
    J Urol; 2007 May; 177(5):1851-5. PubMed ID: 17437834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Development and Validation of Prostate Cancer-specific Physician-Hospital Networks.
    Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Bekelman JE; Nelson JB; Bynum JPW; Barnato AE; Kahn JM
    Urology; 2020 Apr; 138():37-44. PubMed ID: 31945379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.